Across TCGA pan-cancer cohorts, FOCAD mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated FOCAD data layer compared with 23 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher FOCAD mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated FOCAD expression acts as an unfavorable survival marker, although some lineages such as LUAD and UCEC show a favorable association.

LUAD, UCEC, and CCRCC are the cancer types where FOCAD mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	All	0.999	0.923	.016	7	view →
UCEC	DFS	Median	III,IV	0.880	0.499	.036	4	view →
CCRCC	DFS	Median	III,IV	0.399	0.932	.022	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: FOCAD tumor-vs-normal RNA expression · all FOCAD data types